[go: up one dir, main page]

WO2001096391A3 - 55p4h4: gene exprime dans divers cancers - Google Patents

55p4h4: gene exprime dans divers cancers Download PDF

Info

Publication number
WO2001096391A3
WO2001096391A3 PCT/US2001/019246 US0119246W WO0196391A3 WO 2001096391 A3 WO2001096391 A3 WO 2001096391A3 US 0119246 W US0119246 W US 0119246W WO 0196391 A3 WO0196391 A3 WO 0196391A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
various cancers
gene expressed
fragment
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/019246
Other languages
English (en)
Other versions
WO2001096391A2 (fr
Inventor
Mary Faris
Rene S Hubert
Daniel E H Afar
Elana Levin
Steven Chappell Mitchell
Arthur B Raitano
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Priority to EP01946410A priority Critical patent/EP1294875A2/fr
Priority to AU2001268466A priority patent/AU2001268466A1/en
Publication of WO2001096391A2 publication Critical patent/WO2001096391A2/fr
Publication of WO2001096391A3 publication Critical patent/WO2001096391A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un nouveau gène (désigné 55P4H4) et la protéine pour laquelle il code. Le 55P4H4 manifeste une expression limitée aux tissus dans un tissu adulte normal; il est cependant exprimé de façon aberrante dans plusieurs cancers, y compris le cancer de la prostate, de la vessie, du rein, du poumon, des testicules, de l'os, de l'utérus, du cerveau et des ovaires. De ce fait, 55P4H4 constitue une cible diagnostique et/ou thérapeutique lors des cancers, et le gène 55P4H4 ou un fragment de celui-ci ou encore la protéine pour laquelle il code ou son fragment est utilisé pour éliciter une réponse immunitaire.
PCT/US2001/019246 2000-06-13 2001-06-13 55p4h4: gene exprime dans divers cancers Ceased WO2001096391A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01946410A EP1294875A2 (fr) 2000-06-13 2001-06-13 55p4h4: gene exprime dans divers cancers
AU2001268466A AU2001268466A1 (en) 2000-06-13 2001-06-13 55p4h4: gene expressed in various cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21145400P 2000-06-13 2000-06-13
US60/211,454 2000-06-13

Publications (2)

Publication Number Publication Date
WO2001096391A2 WO2001096391A2 (fr) 2001-12-20
WO2001096391A3 true WO2001096391A3 (fr) 2002-12-05

Family

ID=22786990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019246 Ceased WO2001096391A2 (fr) 2000-06-13 2001-06-13 55p4h4: gene exprime dans divers cancers

Country Status (3)

Country Link
EP (1) EP1294875A2 (fr)
AU (1) AU2001268466A1 (fr)
WO (1) WO2001096391A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2450840B (en) 2006-05-11 2010-12-29 Quark Pharmaceuticals Inc Screening Systems Utilizing RTP801
WO2007141796A2 (fr) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Utilisations thérapeutiques d'inhibiteurs de rtp801l
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009046A1 (fr) * 1997-08-21 1999-02-25 Quark Biotech, Inc. Genes regules au niveau de l'hypoxemie
WO1999051727A2 (fr) * 1998-04-03 1999-10-14 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acides nucleiques humaines extraites des tissus sains d'ovaires
WO2000044902A2 (fr) * 1999-01-29 2000-08-03 G.D. Searle & Co. Biomarqueurs et dosages de carcinogenese
WO2001051513A2 (fr) * 2000-01-14 2001-07-19 Corixa Corporation Sequences associees a une tumeur ovarienne
WO2001057207A2 (fr) * 2000-02-04 2001-08-09 Corixa Corporation Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2001074901A2 (fr) * 2000-03-31 2001-10-11 Scios Inc. Facteurs secretes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009046A1 (fr) * 1997-08-21 1999-02-25 Quark Biotech, Inc. Genes regules au niveau de l'hypoxemie
WO1999051727A2 (fr) * 1998-04-03 1999-10-14 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acides nucleiques humaines extraites des tissus sains d'ovaires
WO2000044902A2 (fr) * 1999-01-29 2000-08-03 G.D. Searle & Co. Biomarqueurs et dosages de carcinogenese
WO2001051513A2 (fr) * 2000-01-14 2001-07-19 Corixa Corporation Sequences associees a une tumeur ovarienne
WO2001057207A2 (fr) * 2000-02-04 2001-08-09 Corixa Corporation Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2001074901A2 (fr) * 2000-03-31 2001-10-11 Scios Inc. Facteurs secretes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL SEQUENCE LIBRARY 2 May 2000 (2000-05-02), TSAI, S.F.: "Genome Sequencing of the Chromosome 4q Region Implicated in Human Hepatocellular Carcinoma Pathogenesis 1 - Homo sapiens genomic DNA, chromosome 4q22-q24, clone:2190A3", XP002196337 *
DATABASE EMBL SEQUENCE LIBRARY 22 July 1997 (1997-07-22), NCI-CGAP: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index http://www.ncbi.nlm.nih.gov/ncicgap - nj15d07.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:986413 3', mRNA", XP002196336 *
DATABASE EMBL SEQUENCE LIBRARY 9 February 2001 (2001-02-09), ADACHI, J., ET AL.: "functional annotation of a full-length mouse cDNA collection - Mus musculus adult male testis cDNA, RIKEN full-length enriched library clone:1700108M02:homolog to CDNA FLJ20500 FIS, CLONE KAT09159, full insert", XP002196338 *
DATABASE TREMBL DATABASE 1 June 2001 (2001-06-01), KAWAI,J., ET AL.: "functional annotation of a full-length mouse cDNA collection", XP002196339 *
TJOA B ET AL: "PRESENTATION OF PROSTATE TUMOR ANTIGENS BY DENDRITIC CELLS STIMULATES T-CELL PROLIFERATION AND CYTOTOXICITY", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 28, no. 1, 1996, pages 65 - 69, XP000605663, ISSN: 0270-4137 *
XUE B-H ET AL: "INDUCTION OF HUMAN CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR PROSTATE- SPECIFIC ANTIGEN", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 30, no. 2, 1997, pages 73 - 78, XP000878867, ISSN: 0270-4137 *

Also Published As

Publication number Publication date
WO2001096391A2 (fr) 2001-12-20
EP1294875A2 (fr) 2003-03-26
AU2001268466A1 (en) 2001-12-24

Similar Documents

Publication Publication Date Title
WO2005062972A3 (fr) Traitement du cancer au moyen de nouveaux anticorps monoclonaux anti-il 13
IL147902A0 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO2002016593A3 (fr) Acide nucleique et proteine correspondante nomme 158p1d7 servant dans le traitement et la detection du cancer de la vesicule et d'autres cancers
WO2001062778A3 (fr) Nouveaux composes
WO2001083739A3 (fr) Polypeptides pellino humains
WO2001077289A3 (fr) Polynucleotides codant de nouvelles proteines secretees
WO2001096391A3 (fr) 55p4h4: gene exprime dans divers cancers
WO2002028889A3 (fr) Antigenes d'haemophilus influenzae et fragments d'adn correspondants
WO2001055391A3 (fr) 84p2a9: proteine specifique de la prostate et du testicule fortement exprimee dans le cancer de la prostate
WO2001062925A3 (fr) 103p2d6: proteine specifique de certains tissus, fortement exprimee dans divers cancers
WO2001077290A3 (fr) Polynucleotides codant pour des nouvelles proteines secretees
WO2001079557A3 (fr) Proteine de fixation gtp pour le traitement et la detection du cancer
WO2004072263A3 (fr) Acide nucleique et proteine correspondante dite 158p1d7, utiles pour le traitement et la detection de cancers de la vessie et autres
WO2001059110A3 (fr) 34p3d7: proteine specifique aux tissus hautement exprimes dans le cancer de la prostate
WO2002018578A3 (fr) Acide nucleique et proteine correspondante denommes 85p1b3 utilises dans le traitement et la detection de cancers
WO2001059115A3 (fr) Le 83p5g4: proteine specifique de tissus fortement exprime dans le cancer de la prostate
WO2001090157A3 (fr) 98p7c3: proteine a homeodomaine fortement exprimee dans divers cancers
WO2003020954A3 (fr) Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer
AU2001289930A1 (en) Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
WO2001031343A3 (fr) Diagnostic et traitement du cancer utilisant des molecules liees au sgp-28
WO2001092524A3 (fr) Gene du type myosine exprime dans le coeur et les muscles humains
WO2002014501A3 (fr) Acides nucleiques et proteines correspondantes appelees phor1-a11 et phor1-f5d6 utiles dans le traitement et la detection du cancer
WO2000042165A3 (fr) Proteine specifique de la moelle osseuse
WO2001075001A3 (fr) Nouveau polypeptide, protéine kinase humaine dépendant de l'adénosine cyclique 9, et poynucléotide codant pour ce polypeptide
WO2000049139A3 (fr) Proteine kinase activee par la caspase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001946410

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001946410

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001946410

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP